Breast cancer follow-up can be less intensive

November 8, 2018, University of Twente
Figure 1. The INFLUENCE nomogram for the time-dependent risk of locoregional relapse, available for consultation at www.utwente.nl/influence and the platform for prediction models www.evidencio.com. Credit: University of Twente

Doctoral research by Annemieke Witteveen at the University of Twente has shown that the number of follow-up visits for women after breast cancer treatment in the Netherlands could be reduced by about 9,000 visits per year. The follow-up could be offered based on the to the risk of recurrence, so that women with a low risk possible would need to revisit the hospital for a mammogram less frequently. Personalized follow-up reduces the burden on patients, care providers and possible the care budget.

Breast Cancer Follow-Up

In the Netherlands, every day almost 50 learn that they have and this number is rising. At the same time the number of women who die of breast cancer is falling, because treatments have been improved and the disease is discovered at an earlier stage. After treatment for breast cancer, however, women run the that the disease returns: this is called a relapse. About 4% of women have a relapse in the same breast, and about 5% develop a new tumour in the other breast, within ten years of treatment. The aim of follow-up visits is to detect a relapse as early as possible, because this improves the outcome for the patient.

Differences in Relapse Risk

Although breast cancer treatment is being provided in an increasingly personalized way, this is not the case for follow-up: this is still based on consensus, and is not tailored to the actual risk that a patient runs. Witteveen: "Right now breast cancer follow-up is the same for everyone for the first five years: a mammogram and physical examination every year. After five years, according to current guidelines, follow-up depends on the patient's age. However, different patients have different relapse risks, so it would be more logical for women who run a low risk to be given less frequent follow-up visits and women with a high risk to be given follow-up for perhaps longer than five years. My research revealed that women with a higher risk were actually having fewer follow-up visits than women with a lower risk. About half of all relapses are discovered by patients themselves, and not during a follow-up visit. And although follow-up can have reassuring results, a mammogram is not a pleasant thing to undergo and follow-up visits can cause  anxiety and uncertainty. So if certain women run a very low risk of relapse, they are actually being given an unnecessary burden. At the same time this follow-up puts an extra burden on care providers – as well as generating additional costs, both for care providers and for patients."

Mirjam Velting, program manager of the Breast Cancer patient coalition Netherlands (BVN): "Follow-up visits are not always medically necessary. This is almost never discussed with the patient,  even though it is a decision moment during the discussions between the care provider and the patient."

Personalize Follow-Up

For these reasons it is important that follow-up is optimized on the basis of a patient's personal risk of relapse. To determine this risk, the Netherlands Cancer Registry (Nederlandse Kankerregistratie, NKR) has been. The NKR registers almost all new cancer cases since 1989, and the data set used for this research comprised almost 50,000 women. Together with the Netherlands Comprehensive Cancer Organization (Integraal Kankercentrum Nederland, IKNL) and care providers, Witteveen developed the INFLUENCE nomogram (www.utwente.nl/influence) with which the risk of a relapse can be determined. Witteveen's research also showed how follow-up can be optimized for every possible risk profile, taking the advantages of early detection and the disadvantages of follow-up (such as discomfort and anxiety) into account. This model allows doctors and patients to assess the risks together and take the most appropriate decisions. Women running a higher risk can be given more frequent check-ups, if required, while patients running a lower risk are spared unnecessary check-ups.

Professor Siesling, one of Witteveen's PhD supervisors: "Together with the care providers united in the  National Breast Cancer group Netherlands (Nationaal Overleg Borstkanker Nederland, NABON), nurses, family doctors and the Breast Cancer Association (Borstkankervereniging), we as researchers are looking how this model can best be implemented in day-to-day practice. This has both statistical as organizational aspects – when and by whom – but it's also about presenting the risk itself in an understandable way. Moreover, follow-up is only a part of the after-care, in which also attention is payed to in example psychosocial complaints."

Witteveen's research was part of the INFLUENCE project (INdividualized FolLow-Up for brEast caNCEr).

Explore further: Weight loss linked to lower breast cancer risk for postmenopausal women

Related Stories

Weight loss linked to lower breast cancer risk for postmenopausal women

October 8, 2018
In a study of postmenopausal women, participants who lost weight had a lower risk of developing invasive breast cancer than those who maintained or gained weight. Published early online in CANCER, a peer-reviewed journal ...

The odds of recurrence of breast cancer in individual patients

July 16, 2015
Scientists of UT research institute MIRA have developed a system that maps out the odds of recurrence of breast cancer in individual patients. On the basis of information about the patient, the original tumour and the treatment ...

Higher risk of in-situ breast CA, ovarian tumors with fertility Tx

July 17, 2018
(HealthDay)—For women undergoing assisted reproduction, there is no increased risk of corpus uteri or invasive breast cancer, but there is an increased risk of ovarian cancer and in situ breast cancer, according to a study ...

IVF treatment not associated with increased risk of breast cancer

July 19, 2016
Among women undergoing fertility treatment in the Netherlands between 1980 and 1995, the use of in vitro fertilization (IVF) compared with non-IVF treatment was not associated with increased risk of breast cancer after a ...

Increased adiposity tied to lower premenopausal breast CA risk

June 25, 2018
(HealthDay)—Across body mass index (BMI) distribution, increased BMI is associated with reduced risk of premenopausal breast cancer, according to a study published online June 21 in JAMA Oncology.

Many breast cancer survivors not getting needed mammograms

May 31, 2018
(HealthDay)—After surviving a diagnosis of breast cancer, women still need regular screening. But many of them, especially black women, aren't getting the mammograms they need, a new study finds.

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.